Bio-rad Laboratories, INC 10-Q quarterly reports

Bio-Rad Laboratories' Q2 2026 report shows flat net sales, with a decline in Life Science offset by modest growth in Clinical Diagnostics, while managing significant market uncertainties and a substantial investment portfolio.

Bio-Rad Laboratories reported a net loss of $527.1 million for Q1 2026, primarily driven by a significant decline in the fair market value of its investment in Sartorius AG.

Bio-Rad Laboratories reported a net loss for the third quarter of 2025, primarily driven by a significant decline in the fair value of its investment in Sartorius AG, despite a slight increase in net sales.

Bio-Rad Laboratories reported a significant net income of $317.8 million for the second quarter of 2025, primarily due to a $334.4 million gain from its Sartorius AG equity investment, despite a slight 2.1% increase in net sales and ongoing operational cost pressures.

Bio-Rad Laboratories' Q1 2025 sales decreased by 4.2% year-over-year, impacted by challenges in the life science segment and restructuring activities.

Bio-Rad Laboratories' Q3 2024 results show a net income of $653.2 million, heavily influenced by gains in fair market value of equity securities, while facing challenges in the Life Science segment.

Bio-Rad Laboratories reported a substantial net loss for the second quarter of 2024, primarily due to a decrease in the fair market value of equity securities and a challenging market environment for its Life Science segment.

Bio-Rad Laboratories reports a significant increase in net income for Q1 2024, driven by gains in equity securities, despite a decrease in overall revenue.